biologic

Recombivax, Recombivax Hb

Hepatitis B Vaccine (Recombinant)

Loss of exclusivityJuly 1998projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameRecombivax, Recombivax Hb
Active ingredientHepatitis B Vaccine (Recombinant)
Strength40UG/ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 1986
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Recombivax, Recombivax Hb patent cliff — loss of exclusivity July 1998 | CliffBio